Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.

doi:10.1093/jnci/djw148

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.

Journal of the National Cancer Institute - 1 Nov 2016

Ter Brugge Petra, Kristel Petra, van der Burg Eline, Boon Ute, de Maaker Michiel, Lips Esther, Mulder Lennart, de Ruiter Julian, Moutinho Catia, Gevensleben Heidrun, Marangoni Elisabetta, Majewski Ian, Józwiak Katarzyna, Kloosterman Wigard, van Roosmalen Markus, Duran Karen, Hogervorst Frans, Turner Nick, Esteller Manel, Cuppen Edwin, Wesseling Jelle, Jonkers Jos

Abstract excerpt

BACKGROUND: Although BRCA1-deficient tumors are extremely sensitive to DNA-damaging drugs and poly(ADP-ribose) polymerase (PARP) inhibitors, recurrences do occur and, consequently, resistance to therapy remains a serious clinical problem. To study the underlying mechanisms, we induced therapy resistance in patient-derived xenograft (PDX) models of BRCA1-mutated and BRCA1-methylated triple-negative breast cancer....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Fusion

Share to Genes, BRCA1

Share to Melphalan

Share to Neoplasm Transplantation

Share to Phthalazines

Share to Piperazines

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed

Identifiers

PMID: 27381626
DOI: 10.1093/jnci/djw148

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.PMID 27381626Read ↗

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.Semantic proximity Read ↗

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.Semantic proximity Read ↗

Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.Semantic proximity Read ↗

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in <i>BRCA1/2</i> -mutant metastatic breast cancerSemantic proximity Read ↗

Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast CancerSemantic proximity Read ↗

BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug ResistanceSemantic proximity Read ↗

Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?Semantic proximity Read ↗

Drug resistance to targeted therapies: Déjà vu all over againSemantic proximity Read ↗

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancerSemantic proximity Read ↗

Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant stateSemantic proximity Read ↗

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?Semantic proximity Read ↗

Drug resistance in the mouse cancer clinicSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.